Hypertension Treatments

Find Hypertension Treatments

Generic Name

Losartan

Brand Names

ARBLI, Losortan, Hyzaar, Cozaar

FDA approval date: April 06, 2010

Classification: Angiotensin 2 Receptor Blocker

Form: Tablet, Suspension

What is ARBLI (Losartan)?

Hypertension Losartan potassium and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients. Hypertensive Patients With Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets USP are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.

Approved To Treat

Hypertension

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Load-Dependent Arterial Stiffness to Optimize Blood Pressure Management in Older Veterans (LOADED BP)

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Other

Study Phase: Not Applicable

Summary: Hypertension is a common and treatable disorder that remains the leading preventable cause of heart disease. Blood pressure treatment relies mainly on upper arm blood pressure readings and ignores blood vessel physiology and underlying individual genetic information. Older Veterans with hypertension are less likely to be treated to goal blood pressure because there are conflicting recommendations ...

Investigation of the Effectiveness of Exercise and Anti-Fibrotic Approaches in Frozen Shoulder

Enrollment Status: Recruiting

Publish Date: April 07, 2026

Intervention Type: Other, Drug

Study Phase: Not Applicable

Summary: The purpose of this clinical study is to investigate the efficacy of losartan as an antifibrotic approach in addition to a physiotherapy program in patients diagnosed with frozen shoulder. The effects of losartan use on pain intensity, shoulder joint range of motion, functional status, and pain catastrophizing level will be evaluated and compared with the outcomes of patients participating in a ph...

A Prospective, Randomized, Controlled Clinical Pilot Trial Investigating the Partial Down-titration of Guideline-directed Medical Therapy in Patients With Heart Failure in Remission.

Enrollment Status: Recruiting

Publish Date: April 07, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: Heart failure (HF) is a chronic condition that is characterized by a weakened and enlarged heart. It typically causes symptoms such as breathlessness and swelling of the legs, and it is a serious illness that shortens life expectancy. In recent years, new medicines have been developed that can improve heart function and help patients with HF live longer. HF patients with reduced heart function typ...

View All Clinical Trials

Related Latest Advances

Alterations in the testicular lipidome after tumor irradiation and their potential modulation by long-term losartan treatment.

Journal: International journal of radiation biology

Published: March 20, 2026

Angiotensin signaling is essential for stress erythropoiesis but causes retention of dysfunctional mitochondria in RBCs.

Journal: JCI insight

Published: March 20, 2026

Renal Denervation in a Patient With Resistant Hypertension Using a Second-Generation Multi-electrode Catheter in Puerto Rico: A Non-pharmacological Technique for Resistant Arterial Hypertension.

Journal: Cureus

Published: March 10, 2026

View All Latest Advances

Brand Information

ARBLI (losartan potassium)

WARNING:FETAL TOXICITY

When pregnancy is detected, discontinue

1DOSAGE FORMS AND STRENGTHS

Arbli (losartan potassium) oral suspension, 10 mg/mL, is a white, translucent suspension with a peppermint odor.

2CONTRAINDICATIONS

Arbli is contraindicated:

In patients who are hypersensitive to any component of this product.
For co-administration with aliskiren in patients with diabetes.

3OVERDOSAGE

Significant lethality was observed in mice and rats after oral administration of 1,000 mg/kg and 2,000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m

Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.

Neither losartan nor its active metabolite can be removed by hemodialysis.

4DESCRIPTION

Losartan potassium is an angiotensin II receptor blocker acting on the AT

Its empirical formula is C

Losartan potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone. Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of losartan.

Arbli is available as a white, translucent oral suspension with a peppermint odor. Each mL contains 10 mg losartan potassium (equivalent to 9.2 mg losartan), inactive ingredients are: hypromellose, methyl paraben, natural peppermint flavor, polyethylene glycol, povidone, propyl paraben, propylene glycol, purified water, simethicone, sodium phosphates, sucralose, and xanthan gum.

5HOW SUPPLIED

Arbli (losartan potassium)is a white, translucent oral suspension. Each mL contains 10 mg losartan potassium (equivalent to 9.2 mg losartan). It is supplied as 165 mL in a high-density polyethylene (HDPE) bottle with a child-resistant cap and tamper-evident seal. Shake for 20 seconds prior to each use.

NDC 83245-053-06

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.

Store and dispense in original container. Once the bottle is opened, use it within 60 days.

6PATIENT COUNSELING INFORMATION

Administration Information

Instruct patients or caregivers to use oral dosing syringe(s) or an oral dosing cup to correctly measure the prescribed amount of medication. Inform patients that oral dosing syringe(s) or an oral dosing cup may be obtained from their pharmacy.

Pregnancy

Advise pregnant women and females of reproductive potential of the potential risk to the fetus and to inform their healthcare providers of a known, suspected, or planned pregnancy during treatment with losartan

Lactation

Advise women not to breastfeed during treatment with Arbli and for 2 days after the last dose

Potassium Supplements

Advise patients receiving losartan not to use potassium supplements or salt substitutes containing potassium without consulting their healthcare provider

Manufactured for:

Scienture LLC

Commack, NY 11725

Distributed by:

Scienture LLC

Commack, NY 11725

10/25-R1

PPM-0085

7PRINCIPAL DISPLAY PANEL